Immunotherapy Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Immunotherapy
Research on immunotherapy reported by scientists at Harvard University
November 26th, 2008
According to recent research from the United States, "In 1992, high-dose bolus interleukin (IL)-2 was granted Food and Drug Administration approval based on its ability to produce durable complete responses in a small number of patients with metastatic renal cell carcinoma (RCC). However, the substantial toxicity and limited efficacy that is associated with IL-2 has narrowed its application to highly selected patients treated at specialized centers." "In recent years, the relative merits of low- and high-dose cytokine regimens have been clarified by the results of 4 randomized trials. Taken together, these studies suggest that highdose IV bolus IL-2 is Superior in terms...
Source: Immunotherapy Weekly (2008-11-26)
|
